AAV8 Mutant Capsids Enhancing Transduction and Antibody Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face challenges in achieving effective transduction and resistance to neutralizing antibodies, limiting their efficiency in targeting specific tissues and maintaining long-term gene expression.
Innovation Solution
Development of AAV8 mutant capsids with specific mutations in regions such as aa 263-267, 457-459, and 583-597, combined with swapping VP1 and VP2 unique regions from different AAV serotypes, to enhance transduction efficiency and evade neutralizing antibodies, resulting in improved AAV3G1, AAV8.T20, and AAV8.TR1 capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV8 capsid is used for gene delivery, then transduction efficiency in liver and muscle is improved, but resistance to neutralizing antibodies is insufficient
Solution Approach 1:
The patent introduces specific point mutations at localized regions of the AAV8 capsid (amino acid positions 263-267, 457-459, and 583-597) to alter antibody binding sites while preserving overall capsid structure and transduction function. This local modification approach maintains productivity while improving reliability against neutralizing antibodies.
Solution Approach 2:
The patent creates hybrid capsid structures by swapping VP1 and VP2 unique regions between different AAV serotypes (e.g., AAV2/8, AAV5/8 chimeras). This composite approach combines advantageous properties from different serotypes, achieving both high transduction efficiency and enhanced antibody resistance.
2Reliability
If capsid mutations are introduced to evade neutralizing antibodies, then antibody resistance is improved, but transduction efficiency may be reduced
Solution Approach 1:
The patent systematically varies amino acid sequences at specific capsid positions to optimize the balance between antibody resistance and transduction efficiency. By testing multiple mutant variants (e.g., different combinations of mutations at positions 263-267, 457-459, 583-597), the invention identifies parameter combinations that simultaneously improve both reliability and productivity.
Solution Approach 2:
The mutations are strategically placed at specific epitope regions rather than throughout the entire capsid, allowing antibody evasion while preserving critical transduction domains. This localized modification ensures that essential functions (cell attachment, endocytosis, uncoating) remain intact while neutralizing antibody binding is disrupted.
3Adaptability or versatility
If VP1 and VP2 unique regions are swapped from different AAV serotypes, then versatility in targeting different tissues is improved, but capsid structure complexity increases
Solution Approach 1:
The patent divides the capsid protein into functional domains, specifically swapping only the unique regions of VP1 and VP2 between serotypes while maintaining the conserved regions. This segmentation allows independent optimization of tissue targeting (via unique regions) and structural integrity (via conserved regions), achieving versatility without excessive complexity.
Solution Approach 2:
The chimeric capsids are designed to perform multiple functions: the conserved regions maintain basic viral assembly and cell entry, while the swapped unique regions provide serotype-specific tissue tropism. This multi-functionality allows a single capsid design to achieve both structural stability and diverse targeting capabilities.
Data Source
AI summary
Provided herein are AAV8 mutant capsids and rAAV comprising the same. In one embodiment, vectors employing the AAV8 mutant capsid show increased transduction in a selected tissue as compared to AAV8.